Page 121 - 2020_01-Haematologica-web

Immunosuppressive therapy in myelodysplastic syndromes
dromes. JAMA. 2011;305(8):814-819.
12. Stahl M, DeVeaux M, de Witte T, Neukirchen J, et al. The use of immunosup- pressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018;2(14):1765-
1772.
13. XiaoL,QiZ,QiushengC,etal.Theuseof
selective immunosuppressive therapy on myelodysplastic syndromes in targeted pop- ulations results in good response rates and avoids treatment-related disease progres- sion. Am J Hematol. 2012;87(1):26-31.
14. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2019: Myelodysplastic syndromes. 2019 [cited 2018 20.12.2018]; Available from: https://www.nccn.org/store/login/login.asp x?ReturnURL=https%3a%2f%2fwww.ncc n.org%2fprofessionals%2fphysician_gls%2 fPDF%2fmds.pdf
15. Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99(3):699-705.
16. Komrokji RS, Mailloux AW, Chen DT, et al. A phase II multicenter rabbit anti-thymo- cyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica. 2014;99(7):1176-1183.
17. Kadia TM, Borthakur G, Garcia-Manero G, et al. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony- stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol. 2012;157(3):312-320.
18. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospec- tive randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-- SAKK 33/99. J Clin Oncol. 2011;29(3):303- 309.
19. Sloand EM, Olnes MJ, Shenoy A, et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol. 2010;28(35):5166-5173.
20. Deeg HJ, Gotlib J, Beckham C, et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia. 2002;16(2):162-164.
21. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 2003;102(8):3025-3027.
22. Lim ZY, Killick S, Germing U, et al. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 2007;21(7):1436-1441.
23. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505-2511.
24. Stroup DF, Berlin JA, Morton SC, et al. Meta- analysis of observational studies in epidemi- ology: a proposal for reporting. Meta-analy- sis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012.
25. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modifi- cation of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-425.
26. Downs SH, Black N. The feasibility of creat- ing a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377-384.
27. Collaboration TC. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.02011. 2011.
28. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137(3):156-163.
29. Yamada T, Tsurumi H, Kasahara S, et al. Immunosuppressive therapy for myelodys- plastic syndrome: efficacy of methylpred- nisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol. 2003;129(8):485-491.
30. Yazji S, Giles FJ, Tsimberidou AM, et al. Antithymocyte globulin (ATG)-based thera- py in patients with myelodysplastic syn- dromes. Leukemia. 2003;17(11):2101-2106.
31. Deeg HJ, Jiang PY, Holmberg LA, et al. Hematologic responses of patients with MDS to antithymocyte globulin plus etaner- cept correlate with improved flow scores of marrow cells. Leuk Res. 2004;28(11):1177- 1180.
32. Scott BL, Ramakrishnan A, Storer B, et al. Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol. 2010;148(6):944- 947.
33. Steensma DP, Dispenzieri A, Moore SB, et al. Antithymocyte globulin has limited effi- cacy and substantial toxicity in unselected anemic patients with myelodysplastic syn- drome. Blood. 2003;101(6):2156-2158.
34. Killick SB, Mufti G, Cavenagh JD, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120(4):679-684.
35. Stadler M, Germing U, Kliche KO, et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modu- lating therapy in patients with low-risk myelodysplastic syndromes. Leukemia. 2004;18(3):460-465.
36. Broliden PA, Dahl IM, Hast R, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non- sideroblastic myelodysplastic syndromes. Haematologica. 2006;91(5):667-670.
37. Garg R, Faderl S, Garcia-Manero G, et al. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syn- drome. Leukemia. 2009;23(7):1297-1302.
38. Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010;149(5):706-710.
39. Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome--results of a pilot
study. Br J Haematol. 2005;128(5):625-630. 40. Remacha AF, Arrizabalaga B, Bueno J, et al. Treatment with mycophenolate mofetil fol- lowed by recombinant human erythropoi- etin in patients with low-risk myelodysplas- tic syndromes resistant to erythropoietin treatment. Haematologica. 2010; 95(2):339-
340.
41. Ishikawa T, Tohyama K, Nakao S, et al. A
prospective study of cyclosporine A treat- ment of patients with low-risk myelodys- plastic syndrome: presence of CD55(- )CD59(-) blood cells predicts platelet response. Int J Hematol. 2007;86(2):150-157.
42. Haider M, Al Ali N, Padron E, et al. Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2016;16 Suppl:S44-S48.
43. Komrokji RS, Haider M, Al Ali NH, et al. Somatic Gene Mutations Serve As Molecular Biomarkers Predictive for Response to Immunosuppressive Therapy (IST) in Myelodysplastic Syndromes (MDS). Blood. 2015;126(23):1664.
44. Shallis RM, Chokr N, Stahl M, et al. Immunosuppressive therapy in myelodys- plastic syndromes: a borrowed therapy in search of the right place. Expert Rev Hematol. 2018;11(9):715-726.
45. Fenaux P, Platzbecker U, Mufti GJ, et al. The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo- Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood. 2018;132(Suppl 1):1.
46. Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017;18(10):1338-1347.
47. Komrokji R, Garcia-Manero G, Ades L, et al. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematol. 2018;5(2):e63-e72.
48. Wang C, Yang Y, Gao S, et al. Immune dys- regulation in myelodysplastic syndrome: Clinical features, pathogenesis and thera- peutic strategies. Crit Rev Oncol Hematol. 2018;122:123-132.
49. Kojima S, Ohara A, Tsuchida M, et al. Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosup- pressive therapy in children. Blood. 2002;100(3):786-790.
50. Santini V. Treatment of low-risk myelodys- plastic syndromes. Hematology Am Soc Hematol Educ Program. 2016;2016(1):462- 469.
51. Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring sys- tem for myelodysplastic syndromes. Blood. 2012;120(12):2454-2465.
52. Ogata M, Ohtsuka E, Imamura T, et al. Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review. Int J Hematol. 2004;80(1):35-42.
haematologica | 2020; 105(1)
111